Robalzotan AstraZeneca

Current Opinion in Investigational Drugs

Volumn 1, Issue 2, 2000, Pages 236-240

  Mucke, H A M ^a  

^a NONE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; LITHIUM; MELATONIN; MIRTAZAPINE; MODAFINIL; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NOMELIDINE; PAROXETINE; PHENELZINE; PINDOLOL; PRAZOSIN; RISPERIDONE; ROBALZOTAN; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; THYROXINE;

ANORGASMIA; ANXIETY NEUROSIS; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG METABOLISM; DRUG POTENTIATION; EXPERIMENTAL MODEL; HUMAN; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR BLOCKING; RECEPTOR INTRINSIC ACTIVITY; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BENZOPYRANS; DRUGS, INVESTIGATIONAL; HUMANS; MIGRAINE DISORDERS; PATENTS; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033755658     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299
2. Merrill Lynch: United Kingdom Pharmaceuticals: Zeneca
3. In vivo labelling of the mouse brain 5-hydroxytryptamine1A receptor with the novel selective antagonist 3H-NAD-299
4. AstraZeneca progresses key products and aims to double product portfolio value every five years
5. PET determination of robalzotan (NAD-299)-induced 5-HT(1A) receptor occupancy in the monkey brain
6. Electrophysiological comparison of 5-hydroxytryptamine1A receptor antagonists on dorsal raphe cell firing
7. Metabolite studies measured by HPLC in monkey plasma of the new 5-HT1A radioligand [C-11]NAD-299
8. 11C]NAD-299, a radioligand for visualization of the 5-HT(1A) receptor
9. The 5-HT(1A) receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing
10. In vivo intrinsic efficacy of the 5-HT1A receptor antagonists NAD-299, WAY-100,635 and (S)-(-)-UH-301 at rat brain monoamine receptors
11. Facilitation and inhibition of male rat ejaculatory behaviour by the respective 5-HT(1A) and 5-HT(1B) receptor agonists 8-OH-DPAT and anpirtoline, as evidenced by use of the corresponding new and selective receptor antagonists NAD-299 and NAS-181
12. 3H]NAD-299, a new selective 5-HT(1A) receptor antagonist
13. Differential regional antagonism of 8-OH-DPAT-induced decrease in serotonin synthesis by two 5-HT(1A) receptor antagonists
14. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment
15. Paroxetine and pindolol: A randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency
16. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: A double-blind, placebo-controlled study
17. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius
18. Buspirone augmentation of antidepressant therapy
19. Mirtazapine augmentation in the treatment of refractory depression
20. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression
21. Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies
22. Modafinil augmentation of antidepressant treatment in depression
23. Use of slow-release melatonin in treatment-resistant depression
24. Treatment of refractory chronic depression and dysthymia with high-dose thyroxine
25. 11)C]WAY-100635 in psychotropic drug development
26. AstraZeneca